1. Home
2. Opinions

Comments On Stanley Druckenmiller’s f13 portfolio Update

Written By

Dan Buckley

Written By

Dan Buckley

Head Market Analyst

Dan Buckley is an US-based trader, consultant, and analyst with a background in macroeconomics and mathematical finance. As DayTrading.com's chief analyst, his goal is to explain trading and finance concepts in levels of detail that could appeal to a range of audiences, from novice traders to those with more experienced backgrounds. Dan's insights for DayTrading.com have been featured in multiple respected media outlets, including the Nasdaq, Yahoo Finance, AOL and GOBankingRates.

» Dan Buckley Profile Page

Edited By

James Barra

Edited By

James Barra

Head of Content and Media Lead

James is Head of Content and a brokerage expert with a background in financial services. A former management consultant, he's worked on major operational transformation programmes at top European banks. A trusted industry name, James's work at DayTrading.com has been cited in publications like Business Insider.

» James Barra Profile Page

Fact Checked By

William Berg

Fact Checked By

William Berg

Head Legal Analyst & Securities Law Expert

William contributes to several investment websites, leveraging his experience as a consultant for IPOs in the Nordic market and background providing localization for forex trading software. William has worked as a writer and fact-checker for a long row of financial publications.

» William Berg Profile Page

Updated

Feb 16, 2026

This article was published on June 24, 2025

Druckenmiller follows a top-down, macro-driven, and opportunistic strategy. It uses big-picture macro calls, then zeroes in on bottom-up stock selection.

He and his team identify secular trends and dislocations (like in healthcare, semiconductors, energy), then construct concentrated, asymmetric bets across sectors.

Historically, they also use leverage, hedges, and derivatives, though these aren’t visible in the 13F. The goal is to generate outsized returns by flexibly shifting capital toward high-conviction names while dynamically managing risk.

What’s the takeaway from the SD’s updated portfolio?

• Sharpened focus – Q1 the fund go from 78 to 52 reported positions and a ~$663 M reduction in equity exposure, shifting toward quality names.
• Biggest stakes – Natera (15.7%), Teva (+65%), Coupang (+5%), Woodward, and Philip Morris trimmed.
• New allocations – Major adds in DocuSign, Taiwan Semiconductor (+457%), Insmed (+131%), CCC Intelligent, EQT, Caesars, Roku, Twilio, Capital One, BridgeBio, more.
• Sector tilt – Rotation into tech infrastructure (TSMC, DocuSign, Twilio), energy & natural resources (EQT, Chesapeake, Antero), with selective healthcare and consumer positions.
• Alpha signals – The push into TSM and Insmed might suggest confidence in semiconductor demand and specialized healthcare growth (has been a theme in Druckenmiller’s previous interviews). The exits from airlines and big tech suggest macro or valuation-driven rebalancing.

Is there any deviation in the Duquesne (DV) investing pattern in the latest portfolio update?

Not fundamentally; it remains classic Druckenmiller: concentrated high-conviction positions, large sector shifts, and opportunistic entries/exits.

Q1 2025 suggests an agile rotation, but the strategy’s essence (macro-first, stock-picking/bottom-up second) remains unchanged.

So no major shift, just an updated expression of his model.

Final caveat on 13F filings

13Fs show only disclosed long equity positions 45 days after quarter-end, and omit derivatives, short positions, leverage, private/venture stakes, and timing nuance around builds/liquidations. As such, it’s important for investors curious about institutional flows to not overweight any given line item as if it were the full scope of Druckenmiller’s strategy.